Scancell Holdings (SCLP) RNS Announcements

Add to Alert list
Date Time Source Announcement
04 Sep 2019 07:00 AM
RNS
First Collaboration Agreement for AvidiMab
20 Aug 2019 02:23 PM
RNS
Notice of AGM
20 Aug 2019 07:00 AM
RNS
Final Results for the year ended 30 April 2019
19 Aug 2019 07:00 AM
RNS
Update on the SCIB1 Phase 2 clinical trial
07 Aug 2019 07:00 AM
RNS
Notice of Final Results
01 Jul 2019 07:00 AM
RNS
H1 2019 Business Update
18 Jun 2019 09:16 AM
RNS
Holding(s) in Company
18 Jun 2019 07:00 AM
RNS
Board Appointment
17 Jun 2019 10:45 AM
RNS
Holding(s) in Company
14 Jun 2019 04:41 PM
RNS
Second Price Monitoring Extn
14 Jun 2019 04:35 PM
RNS
Price Monitoring Extension
13 Jun 2019 07:00 AM
RNS
Share Subscription and Issue of Equity to Vulpes
29 May 2019 11:05 AM
RNS
Second Price Monitoring Extn
29 May 2019 11:00 AM
RNS
Price Monitoring Extension
20 May 2019 07:00 AM
RNS
Scancell and CRUK provide an update on SCIB2
10 May 2019 07:00 AM
RNS
Clinical Advisory Board and Update on Modi-1
25 Apr 2019 07:00 AM
RNS
UK approval to start SCIB1 Phase 2 trial
08 Apr 2019 07:00 AM
RNS
Japan patent for Moditope immunotherapy platform
21 Mar 2019 07:00 AM
RNS
Professor Lindy Durrant receives Waldenström award
20 Mar 2019 07:00 AM
RNS
Scancell strengthens IP portfolio
05 Mar 2019 06:27 PM
RNS
Holding(s) in Company
04 Mar 2019 04:40 PM
RNS
Second Price Monitoring Extn
04 Mar 2019 04:35 PM
RNS
Price Monitoring Extension
21 Feb 2019 07:00 AM
RNS
Change of Auditor
31 Jan 2019 07:00 AM
RNS
Interim Results
23 Jan 2019 07:00 AM
RNS
Update on Cancer Research UK's Grand Challenge
21 Jan 2019 07:00 AM
RNS
Appoints Heads of Research and Manufacturing
12 Nov 2018 07:00 AM
RNS
Scancell to Present at Two Conferences
01 Nov 2018 07:00 AM
RNS
Scancell to present at Proactive Investors Forum
30 Oct 2018 05:18 PM
RNS
Results of AGM
30 Oct 2018 07:00 AM
RNS
Identification of 2nd Moditope Cancer Vaccine
24 Oct 2018 09:05 AM
RNS
Second Price Monitoring Extn
24 Oct 2018 09:00 AM
RNS
Price Monitoring Extension
24 Oct 2018 07:00 AM
RNS
Update on SCIB1 Phase 2 Clinical Study
05 Oct 2018 07:00 AM
RNS
Notice of AGM
25 Sep 2018 07:00 AM
RNS
Final Results for the year ended 30 April 2018
18 Sep 2018 07:00 AM
RNS
Notice of Final Results
10 Aug 2018 07:00 AM
RNS
Board Change
09 Aug 2018 07:00 AM
RNS
Agreement
25 Jul 2018 02:45 PM
RNS
Director/PDMR Shareholding
24 Jul 2018 07:00 AM
RNS
Issue of Equity
18 Jul 2018 07:00 AM
RNS
Scancell exercises TriGrid commercial option
23 May 2018 07:00 AM
RNS
Grant of European patent for Moditope platform
11 May 2018 01:11 PM
RNS
Holding(s) in Company
09 May 2018 10:12 AM
RNS
Holding(s) in Company
08 May 2018 07:00 AM
RNS
Result of the Open Offer and PDMR Shareholdings
23 Apr 2018 12:43 PM
RNS
Holding(s) in Company
20 Apr 2018 04:32 PM
RNS
Holding(s) in Company
18 Apr 2018 02:29 PM
RNS
Result of Placing and Subscription and PDMR
18 Apr 2018 11:05 AM
RNS
Second Price Monitoring Extn

Scancell Holdings PLC is a biopharmaceutical company that develops vaccines and other therapies to treat cancer and infectious diseases. Scancell's research focuses on the human immune system and how to use it to develop new treatments. Scancell uses four technology platforms to develop its products: ImmunoBody, Moditope, GlyMab and AvidiMab.

Scancell was founded in 1997 based on research led by Professor Lindy Durrant at the University of Nottingham.

Scancell Holdings PLC is listed on the London Stock Exchange (LSE) as SCLP.

Scancell share price listed at 8p in 2010.

UK 100

Latest directors dealings